Möchten Sie immer auf dem neuesten Stand bleiben?

Leafwell Advances Medical Cannabis as Clinically Validated Solution for Cancer-Related Symptoms and Chronic Pain, Supports Employer-Sponsored Mental Health

These findings reinforce the importance of continuing to deepen our understanding of the underlying biology that drives both growth and resistance.

After a thorough process, management are pleased to undertake this pivotal step for GMP production of PRP for the upcoming Phase 1 FIH clinical study

OCALA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a significant increase in stockholder equity and that the Company has...

Global experts in antibody-drug conjugate (ADC) development, oncology clinical development and early-phase trial design, appointed to support advancement of Byondis’ differentiated ADC pipeline and a...

Global experts in antibody-drug conjugate (ADC) development, oncology clinical development and early-phase trial design, appointed to support advancement of Byondis’ differentiated ADC pipeline and a...

More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC aloneDeep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12,...

NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Bladder cancer is one of the most common, and most overlooked, cancers in the United States, impacting hundreds of thousands of families each year. This...

How chronic disease prevalence, infectious disease testing, AI investment, personalized medicine and regulatory change are shaping the diagnostics industry

An update on corporate progress and reported third quarter financial results as of March 31, 2026 (Year end June 30).